| Literature DB >> 35896559 |
Fu-An Yang1, Hung-Lun Chen1, Chih-Wei Peng2,3, Tsan-Hon Liou4,5, Reuben Escorpizo6,7, Hung-Chou Chen8,9,10.
Abstract
This systematic review and meta-analysis investigated the effect of phonophoresis when various gel types were used. Medline (using PubMed), EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were used to search for relevant studies from the date of their inception to June 28, 2021. We included studies that were randomized controlled trials (RCTs), included patients with a diagnosis of knee osteoarthritis, included treatment with either phonophoresis or therapeutic ultrasound with placebo gel, and reported clinical and functional outcomes. Continuous variables are expressed as standardized mean differences (SMDs) with 95% confidence intervals (CIs). Statistical analysis was performed using RevMan 5.3 software. We initially retrieved 2176 studies and finally analyzed nine RCTs including 423 patients. The intervention group significantly outperformed the control group in pain scores with NSAID gel (SMD = - 0.53, 95% CI [- 1.02, - 0.05], I2 = 73%) and in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) function score with corticosteroid gel (SMD = - 0.96, 95% CI [- 1.47, - 0.44], I2 = 20%). Phonophoresis alleviated pain and improved functional performance. Because of some limitations of this study, additional high-quality, large-scale RCTs are required to confirm the benefits.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35896559 PMCID: PMC9329477 DOI: 10.1038/s41598-022-16084-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Flowchart of article selection.
Characteristics of selected randomized controlled trials.
| Author, year | Therapeutic ultrasound (mode; frequency; intensity; duration) | Intervention group | Control group | Follow up period | Outcome | ||||
|---|---|---|---|---|---|---|---|---|---|
| n | Age in years, mean (SD) | Content of gel | n | Age in years, mean (SD) | Content of gel | ||||
| Ahmed et al., 2019[ | Continuous; 1 MHz; 1 W/cm2; 10 min | 23 | 53.09 (5.46) | Dexamethasone | 23 | 50.59 (6.77) | Placebo | 1 week | Pain score and WOMAC function score |
| Pinkaew et al., 2019[ | Continuous; 1 MHz; 1 W/cm2; 10 min | 20 | 65.20 (8.34) | 20 | 64.30 (9.71) | Placebo | 1 week | Pain score and 6-min walk test | |
| Zhao et al., 2015[ | –; 40 kHz; 5000 Pa; – | 39 | 59.4 (8.9) | Diclofenac | 19 | 60.8 (9.0) | Placebo | 1 month | Pain score, WOMAC function score, and range of motion |
| Oktayoğlu et al., 2014[ | Continuous; 1 MHz; 1.5 W/cm2; 10 min | 20 | 54.55 (8.65) | Diclofenac | 20 | 55.05 (10.08) | Placebo | 3 months | Pain score and WOMAC function score |
| Toopchizadeh et al., 2014[ | –; –; 1.5 W/cm2; 5 min | 19 | 54.6 (6.23) | Dexamethasone | 18 | 56.95 (7.33) | Placebo | 1 week | Pain score, WOMAC function score, and timed up-and-go test |
| Boyaci et al., 2013[ | Continuous; 1 MHz; 1.5 W/cm2; 8 min | 33 | 52.45 (4.80) | Ketoprofen | 33 | 52.58 (7.27) | Placebo | 1 week | Pain score, WOMAC function score, 15-min walking time |
| Luksurapan et al., 2013[ | Continuous; 1 MHz; 1 W/cm2; 10 min | 23 | 59.83 (9.88) | Piroxicam | 23 | 58.00 (11.22) | Placebo | 1 week | Pain score and WOMAC function score |
| Akinbo et al., 2011[ | Continuous; 1 MHz; 1 W/cm2; – | 15 | 64.29 (19.83) | Diclofenac | 15 | 64.92 (10.52) | Placebo | 1 week | WOMAC function score, range of motion, and 20-min walking time |
| Kozanoglu et al., 2003[ | Continuous; 1 MHz; 1 W/cm2; 5 min | 30 | 60.3 (9.2) | Ibuprofen | 30 | 59.4 (8.9) | Placebo | 1 week | Pain score, WOMAC function score, 20-min walking time, and range of motion |
WOMAC, the Western Ontario and McMaster Universities Arthritis Index; SD, standard deviation.
Figure 2Study quality assessment.
Figure 3Forest plot for changes from baseline determined using the pain scores. SD, standard deviation; CI, confidence interval.
Figure 4Forest plot for changes from baseline determined using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) function scores. SD, standard deviation; CI, confidence interval.
Figure 5Forest plot for changes from baseline based on range of motion. SD, standard deviation; CI, confidence interval.
Figure 6Forest plot for improvement in walk test scores. SD, standard deviation; CI, confidence interval.
Sensitivity analysis.
| Content of gel | Outlier(s) | SMD (95% CI) before sensitivity analysis | SMD (95% CI) after sensitivity analysis | |||
|---|---|---|---|---|---|---|
| Pain score | NSAID gel | Zhao et al., 2015[ | 73% | − 0.32 (− 0.67, 0.03) | 38% | |
| Corticosteroid gel | – | − 0.53 (− 1.13, 0.07) | 46% | – | – | |
| WOMAC function score | NSAID gel | Zhao et a.l, 2015[ Akinbo et al., 2011[ | − 0.75 (− 1.63, 0.13) | |||
| 90% | 0.04 (− 0.27, 0.35) | |||||
| 1% | ||||||
| Corticosteroid gel | – | 20% | – | – | ||
| Range of motion | NSAID gel | Kozanoglu et al., 2003[ | 1.07 (− 0.09, 2.22) | 90% | 69% | |
| Corticosteroid gel | – | – | – | – | – | |
| Walk test | NSAID gel | Akinbo et al., 2011[ | − 0.57 (− 1.27, 0.12) | 76% | − 0.23 (− 0.58, 0.12) | 0% |
Significant results are underlined.
WOMAC, the Western Ontario and McMaster Universities Arthritis Index; SMD, standard mean difference; CI, confidence interval.